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Abstract
OBJECTIVE: The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK)
inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepato-
cellular carcinoma (HCC) models with different underlying etiologies in two species. DESIGN: Antiproliferative poten-
tial of BAY 86-9766 and synergistic effects with sorafenib were studied in several HCC cell lines. Relevant pathway
signaling was studied in MH3924a cells. For in vivo testing, the HCC cells were implanted subcutaneously or ortho-
topically. Survival and mode of action (MoA) were analyzed. RESULTS: BAY 86-9766 exhibited potent antiproliferative
activity in HCC cell lines with half-maximal inhibitory concentration values ranging from 33 to 762 nM. BAY 86-9766
was strongly synergistic with sorafenib in suppressing tumor cell proliferation and inhibiting phosphorylation of the
extracellular signal–regulated kinase (ERK). BAY 86-9766 prolonged survival in Hep3B xenografts, murine Hepa129
allografts, and MH3924A rat allografts. Additionally, tumor growth, ascites formation, and serum alpha-fetoprotein
levels were reduced. Synergistic effects in combination with sorafenib were shown in Huh-7, Hep3B xenografts,
and MH3924A allografts. On the signaling pathway level, the combination of BAY 86-9766 and sorafenib led to inhib-
ition of the upregulatory feedback loop toward MEK phosphorylation observed after BAY 86-9766 monotreatment.
With regard to the underlying MoA, inhibition of ERK phosphorylation, tumor cell proliferation, and microvessel den-
sity was observed in vivo. CONCLUSION: BAY 86-9766 shows potent single-agent antitumor activity and acts syner-
gistically in combination with sorafenib in preclinical HCC models. These results support the ongoing clinical
development of BAY 86-9766 and sorafenib in advanced HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the major histologic subtype of pri-
mary liver cancer, accounting for 70% to 85% of cases inmost countries
[1]. In 2008, liver cancer was diagnosed in an estimated 748,300 people
and was responsible for an estimated 695,900 deaths, with the highest
rates found in eastern and southeastern Asia and in central and western
Africa [2]. Although liver cancer is less common in Europe than in parts
of Asia and Africa, the incidence in the West is increasing [2,3].
High 5-year survival rates can be achieved in selected patients with
preserved liver function by using partial hepatectomy in early-stage
HCC, ablative therapy in locoregional disease, and liver transplantation
in unresectable disease [4]. However, HCC constitutes a significant
unmet medical need because of the high proportion of patients diag-
nosed with advanced cancer, as well as the high rates of disease progres-
sion following locoregional therapy. Adding to the complexity, HCC
typically occurs in patients having one of several underlying liver dis-
eases, most commonly chronic infection with hepatitis B virus (HBV)
or hepatitis C virus (HCV).
The mitogen-activated protein kinase pathway—also known as the
RAS/RAF/MEK/extracellular signal-regulated kinase (ERK) pathway
[MAP kinase (MAPK) pathway]—is a ubiquitous intracellular cascade
that transduces signals from cell surface receptors to regulate numerous
cytoplasmic and nuclear proteins involved in cellular proliferation,
survival, differentiation, migration, and angiogenesis [5–7]. Unlike other
solid tumors, mutations in the RAS and RAF genes are rarely found in
HCC [8,9]. Instead, overexpression of RAS, down-regulation of the
natural inhibitors of the MAPK pathway, and overexpression of MEK
and ERK are the mechanisms of MAPK pathway activation in HCC
[10–14].Moreover, ERK overexpression has been correlated with disease
progression in HCC [15].
HBV and HCV may increase risk of HCC through activation of
the MAPK pathway. After integration of HBV DNA into the human
genome, two viral transcription factors (HBx and PreS2 activator)
are expressed, which stimulate MAPK pathway signaling, leading to
cellular proliferation and transformation [16].
Early aspects of alcohol-induced liver damage appear associated
with activation of key signaling pathways, including ERK1/2, which
in turn drives increased expression of various transduction factors,
such as sterol regulatory element binding proteins and early growth
factor response 1 [17]. Physiologically relevant concentrations of
ethanol, corresponding to blood alcohol levels of 0.05 to 0.18 mg/dl,
increase transforming growth factor α levels, leading to activation of
MEK and ERK signaling, cell cycle progression, and cell proliferation
in human HCC cell lines but not in normal human hepatocytes [18].
A recent study has analyzed the phospho-ERK1/2 (pERK1/2) levels
in tumor tissue from patients with HCC related to HBV, HCV, and
chronic alcohol abuse. In patients with HCV infection, 51.9% (27 of
52) showed high pERK levels, 20% (8 of 40) of patients with HBV
had elevated pERK expression levels, and 37.9% (11 of 29) of patients
with ethanol abuse exhibited increased pERK1/2 staining [19].
Sorafenib is a multikinase inhibitor that targets receptor tyrosine
kinases; vascular endothelial growth factor receptors (VEGFRs) 1, 2,
and 3; platelet-derived growth factor β; Fms-related tyrosine kinase 3
(FLT-3); Ret; c-Kit; and serine/threonine kinases RAF-1 and B-RAF
[20,21]. Due to its antiproliferative, antiangiogenic, and proapoptotic
effects, sorafenib is a compound with a potent antitumoral efficacy.
In the phase III Sorafenib Hepatocellular Carcinoma Assessment
Randomized Protocol trial, sorafenib significantly improved overall sur-
vival (OS) and time to progression compared with placebo in patients
with advanced HCC [22]. Sorafenib also improved OS and time to
progression in another phase III trial that enrolled only Asian patients
with advanced HCC [23]. On the basis of these trials, sorafenib is
currently the standard of care for HCC patients with Child-Pugh
class A liver function who have metastatic disease or unresectable dis-
ease not amenable to liver transplantation [24].
BAY 86-9766 (Refametinib; previously RDEA119) is a highly
selective and potent orally available inhibitor of MEK 1 and MEK 2.
The structural, pharmacologic, and pharmacokinetic properties of
BAY 869766 are described in detail in the paper by Iverson et al.
[25]. In a panel of more than 200 tested kinases, only the enzymes
MEK1/2 were inhibited significantly, through the allosteric binding
of BAY 86-9766. The MEK inhibitor BAY 86-9766 displays potent
in vitro and in vivo antitumor activity in multiple preclinical cancer
models, including melanoma, colorectal cancer, non–small cell lung
cancer, epidermal carcinoma, and HCC [21,25], and is currently in
phase I and II clinical trials for various solid tumors.
In the present report, BAY 86-9766 was evaluated as monotherapy
and in combination with sorafenib in four different HCC models. To
reproduce the biology of human cancer as closely as possible, we chose
three orthotopic models. In contrast to commonly used subcutaneous
xenografts, orthotopic models reflect the importance of the tumor
microenvironment. They allow the interaction of organ-specific factors
(for example, fibroblasts, endothelial cells, and inflammatory cells) with
tumor cells [26,27]. These models show metastatic spread and a higher
degree of vascularity compared with ectopic tumors. All of these mecha-
nisms, which are also important in human HCC development, can be
tested only in orthotopic models. In addition, the immune system
might also play a role in response to HCC therapy. To evaluate possible
immunologic effects, two of the four models are syngeneic: the murine
Hepa129 model and the MH3924A rat model.
The human Hep3B model, which is HBV driven, was chosen in
recognition of the fact that three fourths of all liver cancer deaths are
attributed to hepatitis B infection worldwide [28].
Furthermore, we have characterized on the molecular level differ-
ences in the MAPK pathway inhibition profile for sorafenib and BAY
86-9766 in monotreatment and combination treatment.
Materials and Methods
Cell Proliferation Assays
All cell lines were plated in 96-well plates and incubated overnight
at 37°C. For the time zero determination, CellTiter-Glo reagent
(Promega Corporation, Madison, WI) was added to the wells on a
sister plate. The plates were analyzed on a VICTOR3 plate reader
(PerkinElmer Inc, Waltham, MA). Twenty-four hours after cell seed-
ing, test compounds, which were evaluated in serial dilutions at concen-
trations ranging from 300 pM to 10 μM, were added to the wells. Cells
were incubated for 72 hours at 37°C before the CellTiter-Glo lumines-
cence signal was determined on a VICTOR X3 plate reader. The
percentage change in cell growth was calculated by normalizing the
measurements to the extinctions of the time zero point plate (=0%)
and the untreated (0 μM) cells (=100%). The half-maximal inhibitory
concentrations (IC50) were determined by means of a four-parameter
fit using MTS Software (Bayer Software, Berlin, Germany).
Analysis of Combination Effects
The combination effects of BAY 86-9766 and sorafenib in the
72-hour cell proliferation assay were evaluated using combination
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index isobologram analysis. Briefly, cells were plated onto a 384-well
plate with 25 μl of medium. After a 24-hour incubation at 37°C, 5 μl
of medium containing BAY 86-9766 (D1), sorafenib (D2), or the
combination of both compounds at different ratios (0.9 × D1 +
0.1 × D2, 0.7 × D1 + 0.3 × D2, 0.5 × D1 + 0.5 × D2, 0.3 × D1 +
0.7 × D2, and 0.1 × D1 + 0.9 × D2) was used to make serial three-
fold dilutions to generate seven concentration-response curves. Each
experiment was conducted in triplicate.
The mapping of the ratio of half-maximal effective concentration to
half-maximal inhibitory concentration (EC50/IC50) was determined by
means of a four-parameter fit using MTS Software (Bayer Software).
The corresponding component doses of BAY 86-9766 and sorafenib
at the EC50/IC50 were calculated and used for plotting isobolograms.
Multiple-drug effect was analyzed as described by Chou [29], and the
combination index was calculated using the following formula: Com-
bination index = [D1x]/D1′ + [D2x]/D2′, where D1x and D2x refer
to the drug 1 and drug 2 concentration at the EC50/IC50 in combi-
nation, and D1′ and D2′ refer to the EC50/IC50 values of D1 and D2,
respectively, as a single agent. In this analysis, combination indexes of
0 to 0.3, 0.3 to 0.6, and 0.6 to 0.9 were defined as very strong synergy,
strong synergy, and synergy, respectively.
Orthotopic Hep3B HCC Xenograft
Human HBV-driven Hep3B HCC cells were implanted orthotopi-
cally onto female Naval Medical Research Institute (NMRI) nude
mice. Treatment was started on day 8 following implantation with once
daily single-agent BAY 86-9766 (5 or 25 mg/kg), once daily sorafenib
(maximum tolerated dose of 30 mg/kg), or combination of BAY
86-9766 and sorafenib at same doses. Each regimen was administered
to 12 or 13 mice. A control group received vehicle. Levels of HCC
serum marker alpha-fetoprotein (AFP) were determined on days 26
and 42 postimplantation when all animals were still alive. The primary
end point in this model was median survival, which was determined by
Kaplan-Meier analysis.
Allograft Models
Orthotopic rat MH3924A allografts. Female August Copenhagen
Irish (ACI) rats were housed and maintained in accordance with Bayer
Institutional Animal Care. For induction of orthotopic HCC tumors,
rat MH3924A cells (3 × 106) in 50% BD Matrigel (BD Biosciences,
San Diego, CA) were injected into the liver under total body anesthe-
sia. The rats were randomly divided into four treatment groups, each
containing 18 animals. Treatment was started 10 days after tumor cell
injection, at which time the animals showed distinct tumor growth.
BAY 86-9766 (3 mg/kg) and sorafenib (6 mg/kg), or their cor-
responding vehicles, were administered orally once daily at least 4 hours
apart. After the first animal in the vehicle group died, six rats from each
group were killed and dissected to evaluate primary tumor weight and
metastatic spread and to collect tumor samples for immunohisto-
chemical staining. The remaining 12 rats in each group were followed
to determine median survival.
For pharmacokinetic (PK) analysis, sorafenib was administered
5.75 hours after BAY 86-9766, and blood samples for analysis of
plasma BAY 86-9766 and sorafenib concentrations were collected
before and 0.5, 1, 2, 5, 8, and 24 hours after dosing of BAY 86-
9766 on day 14. Samples were collected from a venous catheter into
tubes containing lithium heparin and then centrifuged to isolate the
plasma, which was stored at −20°C until analysis. Samples were
analyzed after precipitation with acetonitrile (1/5, vol/vol) using an
Agilent 1200 HPLC with liquid chromatography/mass spectrometry/
mass spectrometry (LC/MS/MS) detection. Drug concentrations were
quantified by calibration with a standard curve and an internal standard.
Orthotopic Hepa129 HCC allografts. Murine Hepa129 HCC
cells (5 × 105) were implanted orthotopically into the liver female
C3H/He mice. Treatment with BAY 86-9766 (25 mg/kg, once daily)
or vehicle was started 4 days after implantation. Each group contained
10 mice. Starting on day 18, the daily dose of BAY 86-9766 was
reduced to 12.5 mg/kg due to slight body weight loss. The mice were
followed to determine median survival by Kaplan-Meier analysis.
Statistical Methods
Statistical analyses were performed using GraphPad Prism 5. In the
Kaplan-Meier curves, fractional survival (Y) was plotted as a function
of time (X) and groups were compared using the log-rank test using
a significance level of .05. In case of multiple comparisons, a P level
correction was carried out using the Bonferroni method.
For the comparison of immunohistochemistry (IHC) results, tumor
and liver weight, Bonforroni multiple comparison test was used, a very
conservative but proper method in case of comparing only a few groups.
Western Blot Analysis and Immunohistochemistry from
MH3924A Cells and Allograft
See Supplementary Materials and Methods section.
Results
Antiproliferative Activity of BAY 86-9766 as Single Agent
BAY 86-9766was tested as a single agent inHCC cell lines of different
etiologies (Table 1). In each cell line, BAY 86-9766 inhibited cell prolifer-
ation in vitro in a concentration-dependent manner with greater potency
against human HepG2 cells with NRAS mutations (IC50 = 33 nM)
than against human Hep3B and PLC/PRF/5 cells with underlying
HBV infection (IC50 = 366 and 762 nM, respectively). In comparison,
BAY 86-9766 was equipotent with another MEK inhibitor (AZD6244)
in the HepG2 cells but three to four times more potent in the other
cell lines. Besides the human HCC lines, BAY 86-9766 exhibited a
concentration-dependent antiproliferative activity in MH3924A and
Hepa129 cells, with IC50 values of 540 and 502 nM, respectively.
Strong Synergism between BAY 86-9766 and Sorafenib in
Terms of Antiproliferative Effects and Feedback Regulation
As a method of choice to measure in vitro synergy, the combina-
tion index isobologram analysis has been performed as described in
Table 1. Antiproliferative Activity of the MEK Inhibitors BAY 86-9766 and AZD6244 in HCC
Cell Lines.
Cell Line Species Etiology/Genetic Mutation IC50 (nM)
BAY 86-9766 AZD6244
PLC/PRF/5 Human HBV infection 762 3060
Hep3B Human HBV infection 366 1093
HepG2 Human NRAS mutation 33 32
MH3924A Rat Not determined 540 4595
Hepa129 Mouse Not determined 502 2260
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Materials and Methods section. If the combination data points fall on
the hypotenuse, an additive effect is present. If the combination
data points fall on the lower left or on the upper right, synergism or
antagonism is indicated, respectively. BAY 86-9766 showed synergistic
antiproliferative activity when tested in combination with sorafenib
in human Hep3B cells (Figure 1A). Strong synergism, defined by a
combination index of 0.3 to 0.6, was observed for two dose combina-
tions: 0.3 μMBAY 86-9766 + 0.7 μM sorafenib (combination index =
0.33) and 0.5 μM BAY 86-9766 + 0.5 μM sorafenib (combination
index = 0.45; Figure 1A). The other three dose combinations also
exhibited synergy, with the combination index in the range of 0.6 to
0.9. The interaction between BAY 86-9766 and sorafenib was also
explored in the rat MH3924A HCC cell line (Figure 1A). Strong
synergistic antiproliferative activity was evident at four of the five
dose combinations, including the two dose combinations with strong
synergism in the Hep3B cells.
Figure 1. Synergistic antiproliferative activity of BAY 86-9766 and sorafenib in HCC cell lines. Isobologram analysis of the interaction
between BAY 86-9766 and sorafenib in human Hep3B cells and rat MH3924A cells is shown in A. Points below the straight diagonal line
indicate a synergistic interaction. The combination index analysis for the interaction between the two drugs in these HCC lines is also
shown in A (D1, sorafenib; D2, BAY 86-9766). Effects of BAY 86-9766 and sorafenib, as single agents and in combination, in MH3924A
cells are shown in B. Phosphorylation of ERK was more potently blocked due to combination treatment in comparison to BAY 86-9766
and sorafenib monotreatment after 12 hours of compound incubation. Additionally, compensatory up-regulation of phosphorylated MEK
was diminished in the combination-treated cells.
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ERK and MEK phosphorylation was examined in MH3924A cells
and visualized by Western blot analysis. Due to combination treat-
ment with BAY 86-9766 and sorafenib, phosphorylation of ERK was
completely blocked after 12 hours in comparison to monotherapy. In
addition, compensatory up-regulation of phosphorylated MEK signal
after BAY 86-9766 monotreatment was diminished in cells treated with
combination of both agents (Figure 1B).
Efficacy of BAY 86-9766 as Monotherapy and in Combination
with Sorafenib in HCC Xenograft Models
Single-agent BAY 86-9766 (20 mg/kg) caused a small inhibition
in the growth of subcutaneous human Huh-7 HCC xenografts,
which was nearly identical to the growth inhibition observed with
sorafenib (50 mg/kg). In contrast, substantial tumor growth inhibi-
tion was observed when BAY 86-9766 was administered in combi-
nation with sorafenib. At the last assessment, the combination
reduced tumor volume by 70% compared with vehicle-treated con-
trol animals, whereas the two drugs individually reduced tumor vol-
ume by approximately 20%. These results indicate that the
combination of BAY 86-9766 and sorafenib produces synergistic
tumor growth inhibition in Huh-7 xenografts (data not shown).
In the orthotopic HBV-driven human Hep3B xenograft model,
BAY 86-9766 (25 mg/kg) monotherapy was more effective than
sorafenib at its maximally tolerated dose (30 mg/kg) in prolonging
survival, reducing serum AFP levels and exhibiting strong synergism
in improving these end points when combined with sorafenib
(Figures 2A and W1). Median survival in the group treated with
BAY 86-9766 at a daily dose of 25 mg/kg was 60 days, compared
with 52 days in the sorafenib group. When BAY 86-9766 (25 mg/
kg) and sorafenib were administered in combination, median survival
was extended to 80 days—an increase of 70% relative to the vehicle
control—which was significantly greater than the median survival in
all other groups (P = .003, significance level corrected for multiple
comparisons using the Bonferroni method; P = .0008 by the log-rank
Figure 2. Effect of BAY 86-9766 and sorafenib, as single agents and in combination, in the orthotopic HBV-driven human Hep3B
xenograft model. Kaplan-Meier survival curves and results are presented in A; comparison of survival with BAY 86-9766 monotherapy
versus vehicle in the orthotopic murine Hepa129 HCC allograft model is presented in B.
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test). Of note, long-term treatment (up to 55 days) with the combi-
nation was well tolerated. Body weight loss in the group was below
10%, demonstrating long-term tolerability with treatment.
Serum AFP measured on day 26 mirrored the survival results, with
the lowest levels seen in the group receiving BAY 86-9766 (25 mg/kg)
plus sorafenib followed by the group receiving the same dose of
BAY 86-9766 as monotherapy (data not shown). These two groups were
also the ones with the lowest serum AFP levels on day 42 (Figure W1).
However, significant between-group differences in AFP levels on
day 26 or 42 were not seen in multiple comparison statistical tests.
Efficacy of BAY 86-9766 as Monotherapy and in Combination
with Sorafenib in HCC Allograft Models
Single-agent BAY 86-9766 significantly prolonged median survival
in the orthotopic murine Hepa129 HCC allograft model. Treatment
was started on day 4 following implantation at a dose of 25 mg/kg,
once daily, but the dose was reduced to 12.5 mg/kg, once daily, start-
ing on day 18 after borderline weight loss was observed. With this
regimen, median survival was 58 days in the BAY 86-9766 group
compared with 30 days for the vehicle-treated animals (P < .0001 by
log-rank test; Figure 2B).
Figure 3. Effect of BAY 86-9766 and sorafenib, as single agents and in combination, on tumor growth, metastatic spread, and alkaline
phosphatase levels in the orthotopic rat MH3924A allograft model. The primary tumor, which has been cut out and measured on day 21
following orthotopic implantation, is depicted in A. Significance is indicated by asterisk (P < .05). Representative photos of the primary
tumor from rats treated with vehicle control or combination therapy are shown in B. The percentage of animals with metastases is
presented in C. Mean (+SD) serum alkaline phosphatase levels are shown in D.
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Single-agent BAY86-9766 [3mg/kg;maximal tolerated dose (MTD)
determined in the rat model] and single-agent sorafenib (6 mg/kg;
MTD determined in the rat model) reduced primary tumor weight
compared with vehicle control in the orthotopic ratMH3924A allograft
model (not reaching statistical significance; Figure 3A). In comparison,
combination therapy with BAY 86-9766 and sorafenib produced sig-
nificant tumor growth inhibition compared with vehicle control (mean
primary tumor weight: 0.24 vs 1.14 g; P < .05 by Bonferroni multiple
comparison test). All animals in the control group had tumors ≥0.8 g,
whereas 33%, 25%, and 60% of the animals had primary tumors
≤0.2 g in the BAY 86-9766, sorafenib, and combination groups, re-
spectively. The reductions in primary tumor growth were mirrored by
significant decreases in liver weight (Figure W2). Median liver weight
expressed as a percentage of body weight was 3.2% in the BAY 86-
9766 group, 2.8% in the sorafenib group, and 2.5% in the combination
group compared with 4.0% in the vehicle control group (P < .05 for all
comparisons vs control by Bonferroni multiple comparison test).
In the MH3924A allograft model, most animals in the control and
single-agent BAY 86-9766 groups had evidence of tumor metastases,
whereas the lowest rates of metastatic spread were seen in the sorafenib
and combination therapy groups (Figure 3C ). A similar profile was
evident when the number of metastases per animal was analyzed:
Animals in the control group had a mean of three metastatic sites,
whereas a mean of less than one site per animal was found in the
sorafenib and combination therapy groups. However, neither the in-
cidence of tumor metastases nor the number of metastases per animal
differed significantly across treatment groups. Ascites was detected in
60% of the control animals but in none of the animals in the other
Figure 4. Effect of BAY 86-9766 and sorafenib, as single agents and in combination, in MH3924A cells and MH3924A allografts. Inhibitory
effect of BAY 86-9766 on phosphorylation of ERK: pERK staining of liver tumor paraffin sections of animals (A) from (i) vehicle group,
(ii) BAY 86-9766 group, (iii) sorafenib group, and (iv) combination group. The proportions of cells staining positive for Ki-67 are shown in
B. Inhibitory effect of BAY 86-9766 on angiogenesis with staining with von Willebrand factor is shown in C. Significance is indicated by
asterisk (P < .05). Kaplan-Meier survival curves and median survival data are shown in D.
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groups. BAY 86-9766 and combination therapy, but not sorafenib
therapy alone, reduced serum alkaline phosphatase toward levels found
in healthy controls, suggesting that BAY 86-9766 protected the animals
from intrahepatic cholestasis (Figure 3D). Similarly, BAY 86-9766 and
combination therapy, but not sorafenib therapy alone, significantly
reduced Ki-67 staining in tumor specimens compared with vehicle
control (P < .05; Figure 4B). In the survival analysis, combination
therapy prolonged median survival to 56 days, which was greater than
the median survival duration of 45 days with single-agent BAY 86-9766
and 35 days with single-agent sorafenib, and double the survival
duration seen in the vehicle control group (P = .008) after correction
for multiple comparisons using the Bonferroni method (P < .0001 by
the log-rank test; Figure 4D).
ERK phosphorylation was examined in MH3924A allograft tumor
samples and visualized by Western blot analysis. Treatment with BAY
86-9766, but not sorafenib, inhibited ERK phosphorylation in the
tumor lysates (Figure W3). Similarly, BAY 86-9766, as a single-agent
and in combination with sorafenib, but not single-agent sorafenib,
demonstrated inhibition of ERK activation through pERK immuno-
histochemistry analysis of liver tumor specimens compared with vehicle
control (Figure 4A, i–iv). Additionally, the effect on tumor blood vessel
growth was examined in MH3924A model using IHC staining for
von Willebrand factor. The number of tumor blood vessels after treat-
ment with single-agent BAY 86-9766, single-agent sorafenib, and
BAY 86-9766 in combination with sorafenib was significantly lower
when compared with vehicle control–treated cells (Figure 4C). Thus,
treatment with both BAY 86-9766 and sorafenib demonstrates statis-
tically significant antiangiogenic effects, which may contribute to the
inhibition of tumor growth.
Pharmacokinetic Properties
Plasma concentrations of BAY 86-9766 and sorafenib were mea-
sured after 14 days of treatment with 3 and 6 mg/kg once daily (qd)
respectively, in rats with MH3924A allografts (Figure 5). Plasma con-
centrations of BAY 86-9766 show only small changes within a dosing
interval with a peak-trough ratio of about 1.5. The unbound average
plasma concentration of BAY 86-9766 was very close to the antiproli-
ferative IC50 of the drug against MH3924A cells in vitro. Plasma sor-
afenib levels remained about 60-fold below the drug’s in vitro
antiproliferative IC50 against MH3924A but were closer to the IC50
against human umbilical vein endothelial cells. The Cmax and
AUC0–24 of both compounds did not significantly differ between single
compound administration and combination treatment.
Figure 4. (continued).
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Discussion
Sorafenib is the current standard of care for patients with advanced
HCC who have preserved liver function [24]. In two randomized
controlled phase III trials, sorafenib significantly extended survival
compared with placebo; however, median OS in the sorafenib arms
of both studies modestly increased [22,23]. As a result, there is a need
for new and effective HCC treatments capable of further improving
patient outcome.
MEK is an attractive therapeutic target because 1) MEK and its
downstream target, ERK, are frequently overexpressed in HCC, which
correlates with disease progression [13,15]; 2) endogenous inhibitors
of the MAPK pathway, including Raf-1 kinase inhibitory protein and
Spred-1, are frequently downregulated, resulting in increased MEK/
ERK activity [8,12]; 3) increased signaling through the MAPK path-
way results in cellular proliferation, survival, differentiation, migration,
and angiogenesis [5–7]; and 4) pathway activation has been observed
after HBV and HCV infection and under chronic alcohol abuse. BAY
86-9766 is an orally available small molecule that binds to an allosteric
region adjacent to the ATP-binding pocket of MEK and inhibits both
MEK 1 and MEK 2 with high potency and selectivity.
The present experimental studies evaluated whether BAY 86-9766
acts synergistically with sorafenib to block cell proliferation in vitro
and inhibit tumor growth, metastatic spread, and relevant complications
(e.g., ascites, cholestasis) and prolong survival in vivo. The models
covered a wide range of HCC subtypes, including virus-induced and
chemical-induced etiologies. To study the efficacy of BAY 86-9766
in a natural tumor microenvironment, three of the four cell lines
were implanted orthotopically. For comparison, the combination of
BAY 86-9766 and sorafenib was also tested in the Huh-7 subcutaneous
standard xenograft model.
BAY 86-9766 showed potent antiproliferative activity in vitro in
each of the HCC cell lines evaluated. Moreover, BAY 86-9766 in
combination with sorafenib showed strong synergistic effects in sup-
pressing tumor cell proliferation in both human Hep3B cells and rat
MH3924A cells. In these cell lines, the strongest synergistic effect
was seen when the molar concentration of BAY 86-9766 was either
the same as or approximately two-fold lower than the sorafenib con-
centration. Synergistic effects also occur in terms of blocking the
MAPK pathway. Due to combination treatment, compensatory
feedback mechanisms regarding up-regulation of phosphorylated
MEK after BAY 86-9766 monotreatment were diminished and the
phosphorylation of ERK was more potently blocked over a longer
period (12 hours) compared to monotherapy in MH3924A cells. It
has been described that activated ERK phosphorylates and inhibits
CRAF kinase and the inhibition of ERK signaling by allosteric MEK
inhibitors relieves ERK-dependent feedback inhibition of CRAF and
induces MEK phosphorylation in most cells [30–32]. Our hypothesis
is that this mode of action for pMEK feedback regulation is also true
for BAY 86-9766. Single-agent sorafenib showed comparable effects
with single-agent BAY 86-9766 in blocking pERK when MH3924A
cells were incubated with high concentrations of 10 μM. Single-agent
BAY 86-9766 and combination therapy with sorafenib effectively
inhibited pERK signaling in MH3924A allograft models. Contrary
to our cellular experiments, in vivo tumor lysates and immunologic
staining showed no inhibitory effect of sorafenib on phosphorylation
of ERK. It is described that Raf inhibitors (like sorafenib) increase,
in BRAF wild-type cells, the phosphorylation of downstream effec-
tors MEK and ERK at low concentrations (paradoxical activation)
and inhibit the pathway at highest concentration (biphasic regulation)
[33,34]. This is exactly the situation we face in our in vitro and
in vivo studies. The cell line MH3924A is incubated with a very high
sorafenib concentration, and pERK reduction could be observed in
the cells. In the MH3924A allograft model, the plasma sorafenib
levels remained about 60-fold below the cellular IC50, and as expected,
pERK activation is detected in the MH3924A tumors at these low
sorafenib concentrations.
Figure 5. Pharmacokinetics of BAY 86-9766 and sorafenib in rats with orthotopic MH3924A allografts. Unbound plasma concentration–
time curves after last dose of combined treatment with 3 mg/kg qd BAY 86-9766 and 6 mg/kg qd sorafenib (given 5.75 hours later) are
shown in A, with the horizontal lines depicting the IC50 values of the respective drugs in the MH3924A cells in vitro. Pharmacokinetic
parameters for each drug individually and in combination are shown in B.
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BAY 86-9766 also demonstrated potent antitumor activity in the
xenograft and allograft models. As a single agent, BAY 86-9766
inhibited tumor growth in the human Huh-7 HCC xenograft model,
prolonged survival and reduced serum AFP levels in the human Hep3B
HCC xenograft model, and prolonged survival in the murine Hepa129
allograft model. In the rat MH3924A allograft model, BAY 86-9766
monotherapy reduced tumor growth and ascites formation, protected
against cholestasis, and prolonged survival. Positive effects on metastatic
spread could be achieved through sorafenibmonotherapy and combina-
tion therapy. When given in combination, BAY 86-9766 and sorafenib
acted synergistically in reducing tumor growth and prolonging survival
in multiple models, including the human Hep3B HCC xenograft and
the rat MH3924A allograft.
Combination of BAY 86-9766 with sorafenib may achieve syn-
ergistic activity in two ways, namely, 1) blockade of the MAPK
pathway at two different points (RAF with sorafenib and MEK with
BAY 86-9766) or 2) blockade of parallel signaling pathways (block-
ing the MAPK pathway with BAY 86-9766 and blocking VEGFR-
mediated signaling pathways with sorafenib). Evidence favoring
the first possibility has been reported in melanoma cells where the
combination of a BRAF inhibitor and MEK inhibitor enhanced
apoptosis and prevented the onset of resistance [35]. Additionally,
our findings demonstrated that both BAY 86-9766 and sorafenib
monotherapies, as well as BAY 86-9766 + sorafenib combination
therapy, had significant antiangiogenic effects in the MH3924A
HCC model.
Tumor blood vessel formation was inhibited by single-agent BAY
86-9766, single-agent sorafenib, and BAY 86-9766 in combination
with sorafenib. BAY 86-9766 monotherapy also effectively inhibited
pERK signaling. Together, these data provide evidence that sorafenib
and BAY 86-9766 are acting synergistically by blocking parallel
signal pathways; sorafenib is primarily blocking VEGFR-mediated
signaling, while BAY 86-9766 acts directly on the MAPK pathway
in vitro and in vivo.
The rat MH3924A allograft model may shed some light on the
mechanism for in vivo synergism between BAY 86-9766 and sorafenib.
Throughout the 24-hour dosing level, plasma BAY 86-9766 con-
centrations remained close to the drug’s antiproliferative IC50 against
MH3924A cells. These findings suggest that the efficacy of BAY 86-
9766 results from a direct effect on the tumor cells. Although plasma
sorafenib concentrations remained below its antiproliferative IC50
against tumor cells, it was close to its IC50 against endothelial cells,
thereby suggesting that the efficacy of sorafenib may be due to an
indirect effect. Taken together, the antiproliferative effect of BAY 86-
9766 and the antiangiogenic properties of sorafenib might combine
in the MH3924A in vivo model to produce a synergistic antitumoral
effect. Nevertheless, our in vitro combination experiments also indicate
a direct synergistic antiproliferative effect between BAY 86-9766 and
sorafenib in MH3924A tumor cells.
In summary, the models used in these investigations cover mul-
tiple HCC subtypes, including virus-induced and chemical-induced
etiologies. Even in tumor models that show less potent antiprolifera-
tive IC50 values in vitro than the NRAS-mutated HepG2 cell line,
BAY 86-9766 showed great in vivo potency, which emphasizes the
effectiveness of the MEK inhibitor.
The role of the tumor stroma and immunologic interactions
was addressed by the orthotopical transplantation of the allograft
cells in the liver and the inclusion of two models with immuno-
competent animals.
Antitumor efficacy of BAY 86-9766, particularly when used in
combination with sorafenib, was observed in each model, suggesting
that this novel MEK inhibitor has potential for broad usage across
multiple HCC subtypes. BAY 86-9766 exhibited significant single-
agent antitumor activity, but MEK inhibitor monotherapy may not
be sufficient for clinical efficacy in a variety of clinical settings. In
a recent phase II trial, a different MEK inhibitor, selumetinib (AZD
6244), did not produce radiographic responses in patients with ad-
vanced HCC even though there was evidence of ERK inhibition
[36]. The potent synergism observed between BAY 86-9766 and
sorafenib suggests that a combination therapy approach may be a
more promising addition to treatment of HCC. Along these lines,
the results of a phase II clinical trial (NCT01204177) [37] investigating
BAY 86-9766 (50 mg, twice a day) in combination with sorafenib
(400 mg, twice a day) as first-line treatment for patients with advanced
HCC will soon be submitted for publication [37,38].
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Supplementary Materials and Methods
Western Blot Analysis from MH3924A Cells and Allograft
Western blot analysis. MH3924A cells were treated with BAY 86-
9766 (1 μM), sorafenib (10 μM), the combination of both com-
pounds, or medium with 0.1% DMSO for 2, 7, and 12 hours. Cells
were washed with cold phosphate-buffered saline and lysed with
lysis buffer (MSD, Gaithersburg, MD). Shock-frozen tumor samples
from animals of the vehicle and treatment groups from the allograft
MH3924A model were lysed as well.
Twenty micrograms of protein was loaded on a Bis-Tris NuPAGE
gel (Invitrogen, Carlsbad, CA), electrophoresed, and transferred using
iBlot system (Invitrogen) to a polyvinylidenefluoride (PVDF) mem-
brane. Blots were probed with anti-pERK and anti-ERK [phospho-
p44/42 MAPK (Thr202/Tyr204)/p44/42 MAPK (ERK1/2); Cell
Signaling Technology, Inc, Danvers, MA]. Control cell extracts from
Cell Signaling Technology [p44/42 MAPK (ERK1/2)] served as
positive and negative controls. As a secondary antibody, Alexa Fluor
680 goat anti-rabbit IgG (Invitrogen) was used, and detection took
place with the Odyssey Infrared Imaging System.
Immunohistochemistry. Liver tumor tissue from the MH3924A
allograft model was fixed in formalin, transferred to ethanol, and
embedded in paraffin. Sections of 3 μm were cut, and after deparaf-
finization, enzymatic antigen retrieval (Dako Proteolytic Enzymes,
Carpinteria, CA) was carried out. Primary antibodies were used to de-
tect pERK [phospho-p44/42 MAPK (Thr202/Tyr204); Cell Signaling
Technology, Inc], Ki-67 (SP6; Abcam, Cambridge, United Kingdom),
and von Willebrand factor (rabbit polyclonal; Abcam). An appropriate
isotype control was carried along on every slide.
Figure W1. Serum AFP levels were measured on day 42 in the orthotopic HBV-driven human Hep3B xenograft model. Lowest levels of
serum AFP levels were seen in the group receiving BAY 86-9766 (25 mg/kg) sorafenib followed by BAY 86-9766 (25 mg/kg) monotherapy.
Figure W2. Effect of BAY 86-9766 and sorafenib, as single agents
and in combination, on tumor growth of the MH3924A allograft
model. The weight of the liver as a percentage of total body weight
is shown.
Figure W3. Inhibitory effect of BAY 86-9766 on phosphorylation of
ERK: anti-pERK Western blot analysis in MH3924A allografts.
